Research Analysts Set Expectations for ALLO Q2 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Investment analysts at William Blair raised their Q2 2025 earnings per share estimates for Allogene Therapeutics in a report released on Wednesday, May 14th. William Blair analyst S. Corwin now expects that the company will post earnings of ($0.26) per share for the quarter, up from their previous forecast of ($0.30). The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics' Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.98) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.89) EPS.

Several other brokerages have also issued reports on ALLO. Piper Sandler cut their price objective on Allogene Therapeutics from $9.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Truist Financial cut their price objective on Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Citigroup cut their price objective on Allogene Therapeutics from $8.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, May 15th. HC Wainwright dropped their price objective on Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, March 19th. Finally, Robert W. Baird dropped their price objective on Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Allogene Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $8.44.

Allogene Therapeutics Stock Performance

Shares of ALLO stock traded up $0.07 on Monday, reaching $1.16. 3,128,306 shares of the company's stock traded hands, compared to its average volume of 3,356,145. Allogene Therapeutics has a 12-month low of $0.86 and a 12-month high of $3.78. The company has a market capitalization of $253.73 million, a P/E ratio of -0.74 and a beta of 0.60. The business's 50 day moving average price is $1.45 and its two-hundred day moving average price is $1.89.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.28).

Insider Buying and Selling at Allogene Therapeutics

In other Allogene Therapeutics news, CEO David D. Chang sold 46,668 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the sale, the chief executive officer now directly owns 5,276,569 shares of the company's stock, valued at $10,342,075.24. This represents a 0.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 61,757 shares of company stock valued at $115,873 in the last 90 days. 13.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Allogene Therapeutics

Several large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System raised its holdings in Allogene Therapeutics by 6.0% in the 4th quarter. California State Teachers Retirement System now owns 135,554 shares of the company's stock valued at $289,000 after acquiring an additional 7,685 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in Allogene Therapeutics by 13.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 68,858 shares of the company's stock valued at $101,000 after acquiring an additional 8,183 shares in the last quarter. Invesco Ltd. increased its holdings in Allogene Therapeutics by 7.0% in the 4th quarter. Invesco Ltd. now owns 127,486 shares of the company's stock valued at $272,000 after buying an additional 8,359 shares during the period. ProShare Advisors LLC increased its holdings in Allogene Therapeutics by 25.6% in the 4th quarter. ProShare Advisors LLC now owns 46,082 shares of the company's stock valued at $98,000 after buying an additional 9,388 shares during the period. Finally, Teacher Retirement System of Texas increased its holdings in Allogene Therapeutics by 28.9% in the 4th quarter. Teacher Retirement System of Texas now owns 43,877 shares of the company's stock valued at $93,000 after buying an additional 9,839 shares during the period. Institutional investors and hedge funds own 83.63% of the company's stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).